美丽田园医疗健康（02373）：基本面有强韧性

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.36 [1]. Core Insights - The company achieved a revenue of CNY 3.001 billion in 2025, representing a year-on-year increase of 16.7%, and a net profit attributable to shareholders of CNY 318 million, up 39.0%, which aligns with expectations [6]. - The company continues to show strong fundamentals, with same-store sales growth of 6.9% and a high dividend payout ratio, with a year-end dividend of HKD 0.72 per share [6]. - The company is positioned as a leader in the beauty and health chain service sector, benefiting from a "dual beauty + dual healthcare" strategy, and is expected to leverage high-end consumption recovery trends for mid-term growth [6][10]. Financial Performance - Revenue projections for 2026 and 2027 have been revised upwards to CNY 39.15 billion and CNY 43.15 billion, respectively, reflecting increases of 18.6% and 21.5% [10]. - The company’s gross margin improved to 49.1% in 2025, up 2.8 percentage points year-on-year, driven by cost optimization and acquisitions [8]. - Operating cash flow for 2025 reached CNY 1.0 billion, marking a 25.4% increase year-on-year, demonstrating strong cash generation capabilities [9]. Business Segments - The beauty and wellness services segment generated revenue of CNY 1.658 billion in 2025, up 14.9%, with direct and franchise income growing by 15.8% and 5.9%, respectively [7]. - The medical beauty services segment reported revenue of CNY 1.017 billion, a year-on-year increase of 9.6%, with significant growth in customer traffic and average spending [7]. - The sub-health medical services segment saw remarkable growth, achieving revenue of CNY 326 million, up 62.2%, contributing to 10.9% of total revenue [7]. Valuation Metrics - The company’s projected PE ratio for 2026 is set at 19 times, reflecting its leading position in the beauty chain sector and expected growth from both organic and acquisition strategies [10]. - The report indicates a projected EPS of CNY 1.76 for 2026, with a continued focus on enhancing profitability through operational efficiencies [10].